Advancements In Diagnostics, Treatments and Precision Medicines of Lyme Diseases – A Review

Shamsuddin Sultan Khan^1*, John Anthony Catanzaro¹

Lyme disease's rising incidence, varied symptoms, diagnostic challenges, economic burden, and limited treatments necessitate multifaceted precision medicine-driven approaches for effective management.

Abstract

The incidence of Lyme disease, which is caused by the bacteria Borrelia burgdorferi and is transmitted by ticks in 77% of cases, has significantly increased. Skin rashes, neurological, dermatological, cardiovascular, and musculoskeletal problems are all brought on by the illness. Ten to twenty percent of individuals with post-treatment Lyme disease syndrome (PTLDS) do not improve after receiving treatment. It is essential to comprehend the traits of Borrelia burgdorferi in order to create Lyme disease diagnostic equipment and treatments. Since North America has the highest prevalence of infected black-legged ticks, the disease is spread by their bite. Preventing health issues requires early detection and treatment. Lyme disease is diagnosed using diagnostic methods such as PCR, qPCR, RT-PCR, NAATs, NGS, and multiplex PCR panels. Lyme arthritis treatment, longer courses of oral antibiotics, intravenous antibiotics, and post-treatment Lyme disease syndrome are among the treatments available. Precision medicine, also known as customized medicine, tries to modify medical judgments and treatments for specific patients in light of their distinctive genetic makeup, way of life, and environment. The future treatment of Lyme disease will comprise better diagnostic equipment, sophisticated imaging methods, precision medicine, individualized vaccination plans, and patient-centered research.

Keywords: Lyme disease, complications, treatment, PTLD, precision medicine.

References

Bennett, N. J. (2019). Lyme Disease: Bulls Eye Rash orFever, Headache, Stiff Neck orFacial Palsy orA Swollen Painful Knee. Introduction to Clinical Infectious Diseases: A Problem-Based Approach, 343–354.

Bratton, R. L., Whiteside, J. W., Hovan, M. J., Engle, R. L., & Edwards, F. D. (2008). Diagnosis and treatment of Lyme disease. Mayo Clinic Proceedings, 83(5), 566–571.

Bush, L. M., & Vazquez-Pertejo, M. T. (2018). Tick borne illness—Lyme disease. Disease-a-Month, 64(5), 195–212.

Castiblanco, J., & Anaya, J.-M. (2015). Genetics and vaccines in the era of personalized medicine. Current Genomics, 16(1), 47–59.

Choo-Kang, C., Tang, E., & Mattappallil, A. (2010). The treatment of early lyme disease. In U.S. Pharmacist (Vol. 35, Issue 9, pp. 41–48).

Climate Change Indicators: Lyme Disease | US EPA. (n.d.). Retrieved November 21, 2023, from https://www.epa.gov/climate-indicators/climate-change-indicators-lyme-disease

Cox, T. L. (2020). Quality of Life of Adults with Lyme Disease. The Chicago School of Professional Psychology.

Cutler, S. J., Vayssier-Taussat, M., Estrada-Peña, A., Potkonjak, A., Mihalca, A. D., & Zeller, H. (2021). Tick-borne diseases and co-infection: Current considerations. Ticks and Tick-Borne Diseases, 12(1), 101607.

Donohoe, H., Pennington-Gray, L., & Omodior, O. (2015). Lyme disease: Current issues, implications, and recommendations for tourism management. Tourism Management, 46, 408–418.

Dumic, I., & Severnini, E. (2018). “Ticking bomb”: the impact of climate change on the incidence of Lyme disease. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018.

Gilbert, L. (2021). The impacts of climate change on ticks and tick-borne disease risk. Annual Review of Entomology, 66, 373–388.

Gomes-Solecki, M., Arnaboldi, P. M., Backenson, P. B., Benach, J. L., Cooper, C. L., Dattwyler, R. J., Diuk-Wasser, M., Fikrig, E., Hovius, J. W., & Laegreid, W. (2020). Protective immunity and new vaccines for Lyme disease. Clinical Infectious Diseases, 70(8), 1768–1773.

Guibinga, G. H., Sahay, B., Brown, H., Cooch, N., Chen, J., Yan, J., Reed, C., Mishra, M., Yung, B., & Pugh, H. (2020). Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine. Human Vaccines & Immunotherapeutics, 16(9), 2114–2122.

Hanson, M. S., & Edelman, R. (2003). Progress and controversy surrounding vaccines against Lyme disease. Expert Review of Vaccines, 2(5), 683–703.

Hook, S. A., Jeon, S., Niesobecki, S. A., Hansen, A. P., Meek, J. I., Bjork, J. K. H., Dorr, F. M., Rutz, H. J., Feldman, K. A., & White, J. L. (2022). Economic burden of reported lyme disease in high-incidence areas, United States, 2014–2016. Emerging Infectious Diseases, 28(6), 1170.

Horowitz, R. I., & Freeman, P. R. (2018). Precision medicine: the role of the MSIDS model in defining, diagnosing, and treating chronic Lyme disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2. Healthcare, 6(4), 129.

Horowitz, R. I., & Freeman, P. R. (2019). Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1. International Journal of General Medicine, 101–119.

Izac, J. R., & Marconi, R. T. (2019). Diversity of the Lyme disease spirochetes and its influence on immune responses to infection and vaccination. Veterinary Clinics: Small Animal Practice, 49(4), 671–686.

Johnson, L., Shapiro, M., & Mankoff, J. (2018). Removing the mask of average treatment effects in chronic Lyme disease research using big data and subgroup analysis. Healthcare, 6(4), 124.

Kullberg, B. J., Vrijmoeth, H. D., van de Schoor, F., & Hovius, J. W. (2020). Lyme borreliosis: diagnosis and management. Bmj, 369.

Lathrop, S. L., Ball, R., Haber, P., Mootrey, G. T., Braun, M. M., Shadomy, S. V, Ellenberg, S. S., Chen, R. T., & Hayes, E. B. (2002). Adverse event reports following vaccination for Lyme disease: December 1998–July 2000. Vaccine, 20(11–12), 1603–1608.

Leimer, N., Wu, X., Imai, Y., Morrissette, M., Pitt, N., Favre-Godal, Q., Iinishi, A., Jain, S., Caboni, M., & Leus, I. V. (2021). A selective antibiotic for Lyme disease. Cell, 184(21), 5405–5418.

Lyme Disease | Lyme Disease | CDC. (n.d.). Retrieved November 21, 2023, from https://www.cdc.gov/lyme/

Lyme Disease Diagnostics Research | NIH: National Institute of Allergy and Infectious Diseases. (n.d.). Retrieved November 22, 2023, from https://www.niaid.nih.gov/diseases-conditions/lyme-disease-diagnostics-research

Lynch, A., Pearson, P., Savinov, S. N., Li, A. Y., & Rich, S. M. (2023). Lactate Dehydrogenase Inhibitors Suppress Borrelia burgdorferi Growth In Vitro. Pathogens, 12(7), 962. https://doi.org/10.3390/pathogens12070962

PBORB - Overview: Lyme Disease, Molecular Detection, PCR, Blood. (n.d.). Retrieved November 21, 2023, from https://www.mayocliniclabs.com/test-catalog/overview/87973

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 | Pfizer. (n.d.). Retrieved November 22, 2023, from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease?fbclid=IwAR3OSzQ2QjLiHslvazolPLGGaePjZNKNG2wwCr66-IecKem8mCU7v0HNpL8

Poland, G. A. (2011). Vaccines against Lyme disease: what happened and what lessons can we learn? Clinical Infectious Diseases, 52(suppl_3), s253–s258.

Pulendran, B., & Ahmed, R. (2011). Immunological mechanisms of vaccination. Nature Immunology, 12(6), 509–517.

Rebman, A. W., & Aucott, J. N. (2020). Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Frontiers in Medicine, 7, 57.

Research points to potential new medical therapy for Lyme disease | ScienceDaily. (n.d.). Retrieved November 21, 2023, from https://www.sciencedaily.com/releases/2023/07/230728113409.htm

Sanchez, E., Vannier, E., Wormser, G. P., & Hu, L. T. (2016). Diagnosis, Treatment and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis and Babesiosis. JAMA, 315(16), 1767. https://doi.org/10.1001/JAMA.2016.2884

Scheiblhofer, S., Weiss, R., Dürnberger, H., Mostböck, S., Breitenbach, M., Livey, I., & Thalhamer, J. (2003). A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes and Infection, 5(11), 939–946.

Schoen, R. T. (2020). Challenges in the diagnosis and treatment of Lyme disease. Current Rheumatology Reports, 22, 1–11.

Signs and Symptoms of Untreated Lyme Disease | Lyme Disease | CDC. (n.d.). Retrieved November 21, 2023, from https://www.cdc.gov/lyme/signs_symptoms/

Soni, D., Van Haren, S. D., Idoko, O. T., Evans, J. T., Diray-Arce, J., Dowling, D. J., & Levy, O. (2020). Towards precision vaccines: lessons from the second international precision vaccines conference. Frontiers in Immunology, 11, 590373.

Sood, S. K., O’Connell, S., & Weber, K. (2011). The emergence and epidemiology of Lyme Borreliosis in Europe and North America. Lyme Borreliosis in Europe and North America: Epidemiology and Clinical Practice, 1–35.

Stricker, R. B., & Johnson, L. (2014). Lyme disease vaccination: safety first. The Lancet Infectious Diseases, 14(1), 12.

Suvarna, R. (2012). Clinical roundup: selected treatment options for Lyme disease. Alternative and Complementary Therapies, 18(4), 220–225.

Table - PMC. (n.d.). Retrieved November 21, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758915/table/T2/?report=objectonly#TFN2

The unmet need for precision medicine in Lyme disease - Clarivate. (n.d.). Retrieved November 21, 2023, from https://clarivate.com/blog/the-unmet-need-for-precision-medicine-in-lyme-disease/

Treatment | Tufts Lyme Disease Initiative. (n.d.). Retrieved November 21, 2023, from https://tuftslymedisease.org/treatment/

Tsang, J. S., Dobaño, C., VanDamme, P., Moncunill, G., Marchant, A., Othman, R. Ben, Sadarangani, M., Koff, W. C., & Kollmann, T. R. (2020). Improving vaccine-induced immunity: can baseline predict outcome? Trends in Immunology, 41(6), 457–465.

Wagemakers, A., Mason, L. M. K., Oei, A., De Wever, B., Van Der Poll, T., Bins, A. D., & Hovius, J. W. R. (2014). Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection. Gene Therapy, 21(12), 1051–1057.

Wang, Y., Esquivel, R., Flingai, S., Schiller, Z. A., Kern, A., Agarwal, S., Chu, J., Patel, A., Sullivan, K., & Wise, M. C. (2019). Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice. The Journal of Infectious Diseases, 219(7), 1146–1150.

Yagupsky, P., Morata, P., & Colmenero, J. D. (2019). Laboratory diagnosis of human brucellosis. Clinical Microbiology Reviews, 33(1), 10–1128.